Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Cisplatin is one of the most widely used anti-cancer drugs. Many patients treated with the drug also have serious side effects like hearing loss.
St. Jude Children’s Research Hospital scientists have identified inherited genetic variations associated with hearing loss in young cancer patients treated with cisplatin, a drug widely used to treat adults with cancer. (Jun J. Yang, PhD, Clinton Stewart, PhD, and Giles Robinson, MD)
St. Jude scientists have linked inherited variations in a second gene to reduced tolerance of a key cancer drug. Findings will aid efforts to improve chemotherapy safety and effectiveness.
St. Jude researchers have identified an inherited variation in the NUDT15 gene that is strongly associated with a low tolerance for a drug that is a mainstay of pediatric ALL treatment. The finding is expected to impact ALL treatment. (Jun J. Yang, PhD)
Study led by St. Jude Children’s Research Hospital finds an inherited gene variation—more common among Hispanic Americans–is tied to increased risk of developing a high-risk form of pediatric leukemia. (Dr. Jun Yang)
Scientists have long known that Hispanic children are at higher risk of developing ALL than white or African-American kids.
Study links inherited genetic variations in a few genes to increased risk of acute lymphoblastic leukemia (ALL) and helps to explain ethnic differences in the cancer’s incidence. (Dr. Jun J. Yang)
Results from a St. Jude Children’s Research Hospital and the Children’s Oncology Group study pinpoint genetic basis for increased leukemia risk facing Hispanic children and provide new hope for closing survival gap. (Dr. Jun Yang)
New research from St. Jude Children’s Research Hospital and the Children’s Oncology Group ties the genetic variation characteristic of Native American ancestry to higher odds cancer will return and highlights a strategy to ease the racial disparities in survival.